- For people with late-stage non-small cell lung cancer (NSCLC) undergoing initial immunotherapy treatment, a key question has been how long they should continue the therapy for the best chance at survival.
- A recent retrospective study examined medical records to compare the outcomes of people who stopped immunotherapy around the two-year mark with those who continued beyond that point.
- The findings suggest that stopping treatment after two years doesn’t seem to negatively affect survival rates, potentially offering reassurance to patients and healthcare providers contemplating whether to discontinue the treatment at that stage.
New research offers perspective on how long treatment with immune checkpoint inhibitor drugs should be given to people with late-stage non-small cell lung cancer (NSCLC).
In particular, researchers investigated whether stopping the immunology treatments after two years affects how long a patient will live.
In their study, recently published in
The study focused on two different treatment paths: one where treatment was stopped at around two years (specifically between 700 and 760 days), and another where treatment continued for more than two years (more than 760 days).
The main objective was to see how long people lived after the 760-day mark using specific statistical models.
Out of 1,091 people who were still receiving immunotherapy for the initial two years, there were two main groups: one that stopped treatment around the two-year mark (113 people), and one that kept going with the treatment (593 people).
People in the group that stopped treatment were generally around 69 years old. Most of them were women and white. This…
Read the full article here